Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Undergraduate Student Research Awards (USRA)

McGill University

$6,000.00

AMPA receptor missense mutations in neurodevelopmental disorders

EF 2024-25

Résumé
Almost 100 million people worldwide or 1-2 % of the global population have been estimated to be affected by intellectual disability (ID). ID is a condition that is often first detected during early childhood and is characterized by significant challenges in both intellectual functioning, such as learning, reasoning and problem solving, as well as adaptive behaviors, such as language, literacy and social skills. ID is also associated with other neurological deficits including autism, seizures, attention deficit, cerebral palsy, vision and hearing deficiencies. Despite this level of understanding, there is still no cure or effective clinical treatment for ID. Emerging evidence, however, increasingly identifies ID as a disorder associated with disrupted neurochemical communication between nerve cells in the brain mediated by the excitatory neurotransmitter, L-glutamic acid (L-Glu). In this grant application, Roberto Charles will study the functional impact of missense mutations found in the genes of patients with ID that encode the AMPA receptor (AMPAR), which is an abundantly expressed neurotransmitter receptor activated by L-Glu. Since AMPARs mediate almost all fast excitatory signaling in neuronal circuits, deficits in their function would be expected to have detrimental effects on the developing and adult brain. The proposed experiments will uncover how missense mutations disrupt AMPAR function and thus will offer an entirely new insight into the molecular origins of ID. Furthermore, information gleaned from our work will provide a valuable framework to develop clinical strategies for the treatment and eventual cure of ID.
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506706
Name
Charles Roberto
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
AMPA receptor missense mutations in neurodevelopmental disorders
Programtype2
Miscellaneous Programs
Orgnameinp2
McGill University
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Ampa Receptor Missense Mutations; Neurodevelopmental Disorders
Abstract
Almost 100 million people worldwide or 1-2 % of the global population have been estimated to be affected by intellectual disability (ID). ID is a condition that is often first detected during early childhood and is characterized by significant challenges in both intellectual functioning, such as learning, reasoning and problem solving, as well as adaptive behaviors, such as language, literacy and social skills. ID is also associated with other neurological deficits including autism, seizures, attention deficit, cerebral palsy, vision and hearing deficiencies. Despite this level of understanding, there is still no cure or effective clinical treatment for ID. Emerging evidence, however, increasingly identifies ID as a disorder associated with disrupted neurochemical communication between nerve cells in the brain mediated by the excitatory neurotransmitter, L-glutamic acid (L-Glu). In this grant application, Roberto Charles will study the functional impact of missense mutations found in the genes of patients with ID that encode the AMPA receptor (AMPAR), which is an abundantly expressed neurotransmitter receptor activated by L-Glu. Since AMPARs mediate almost all fast excitatory signaling in neuronal circuits, deficits in their function would be expected to have detrimental effects on the developing and adult brain. The proposed experiments will uncover how missense mutations disrupt AMPAR function and thus will offer an entirely new insight into the molecular origins of ID. Furthermore, information gleaned from our work will provide a valuable framework to develop clinical strategies for the treatment and eventual cure of ID.
Competitiondate
202405
Approvedterm2
0 yr 6 mths
Pinamesdelim
Charles, Roberto
Approvedterm
0 an 6 mois
Cihrcontribution2
~ $6,000~ $0~